Famed Weight Loss Drugs - Medications Far Pricier In US Than Other Developed Countries
Portfolio Pulse from Vandana Singh
A recent analysis by health policy organization KFF revealed that weight-loss drugs are significantly more expensive in the U.S. than in other developed countries. The high costs, averaging around $1,000 monthly for prolonged treatments, often lead U.S. insurers to exclude these medications from their coverage. The report highlighted the pricing disparity for drugs like Novo Nordisk's Wegovy and Ozempic, and Eli Lilly's Mounjaro. The study also found that while nearly 50% of U.S. adults are interested in prescription weight-loss drugs, this drops to 16% if not covered by insurance.
August 18, 2023 | 11:52 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Eli Lilly's weight-loss drug Mounjaro is significantly more expensive in the U.S. than in other countries. This pricing disparity could impact the company's sales and market penetration in the U.S.
The high cost of Eli Lilly's weight-loss drug Mounjaro in the U.S. could limit its accessibility and usage, potentially impacting the company's revenues and market share in the country.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 80
NEGATIVE IMPACT
Novo Nordisk's weight-loss drugs Wegovy and Ozempic are significantly more expensive in the U.S. than in other countries. This pricing disparity could impact the company's sales and market penetration in the U.S.
The high cost of Novo Nordisk's weight-loss drugs in the U.S. could limit their accessibility and usage, potentially impacting the company's revenues and market share in the country.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 80